Skip to main content

Table 3 Descriptive data of B-non-Hodgkin lymphoma patients (group II)

From: Telomerase reverse transcriptase gene amplification in hematological malignancies

Parameter

B-NHL patients (N = 15)

Age (mean ± SD)

64.3 ± 7.4

Gender, N (%)

 Male

9 (60%)

 Female

6 (40%)

Presentation, N (%)

 DNV

12 (80%)

 Relapse

3 (20%)

Lymphadenopathy, N (%)

15 (100%)

Splenomegaly, N (%)

10 (66.7%)

Hepatomegaly, N (%)

6 (40%)

WBC count (× 109/l) (mean ± SD)

13.5 ± 9.5

Hb level (g/dl) (mean ± SD)

11.4 ± 2.9

Platelet count (× 109/l) (mean ± SD)

154 ± 65

BM lymphocytes % (mean ± SD)

52.5 ± 20

Lactate dehydrogenase (U/l) (mean ± SD)

277.3 ± 73

Karyotype, N (%)

 Normal

8 (53.3%)

 Numerical aberrations

5 (33.3%)

 Structural aberrations

2 (13.3%)

P53 (17p13.1) deletion, N (%)

5 (33.3%)

14q32 rearrangement, N (%)

3 (20%)

TERT amplification, N (%)

7 (46.7%)

Prognosis, N (%)

 I

6 (40%)

 II

2 (13.3%)

 III

7 (46.7%)

  1. BM bone marrow, DNV de novo, Hb hemoglobin, TERT telomerase reverse transcriptase, WBCs white blood cells